BRAF and Lynch syndrome: Moreover, as this was a retrospective study, follow-up of patients was not determined, and evaluation and stratification of risk factors and molecular evaluation (molecular studies for BRAF, MLH1 promotor hypermethylation, and germline mutation analysis for MSI to evaluate Lynch syndrome) of the tumors were not performed.